Add like
Add dislike
Add to saved papers

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.

Anticancer Research 2016 October
AIM: We determined if pre-treatment systemic inflammation would predict poor outcomes in the setting of stereotactic radiosurgery (SRS) for brain metastases.

PATIENTS AND METHODS: The pretreatment albumin concentration, neutrophil and lymphocyte counts, and the platelet-to-lymphocyte ratio (PLR) were evaluated to determine association with intracranial control, local control (LC), initial MRI response (MR), and overall survival (OS) among 70 patients with 152 separate brain metastases treated with SRS alone from 2008-2015.

RESULTS: On multivariate analysis, a higher neutrophil percentage predicted for poor LC, poor initial MR, poor OS and poor intracranial control (p=0.01, p=0.01, p=0.02 and p=0.03, respectively). A lower percentage of lymphocytes predicted for poor LC and poor MR (p=0.01 and p=0.02), and an elevated PLR predicted for poor OS and poor LC (p=0.05 and p=0.04). Additionally, a lower pretreatment albumin concentration predicted for poor LC and OS (p=0.01 and p=0.03).

CONCLUSION: Pretreatment systemic inflammation is associated with poor outcomes post-SRS.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app